Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Nye behandlingsmuligheder ved primær immun trombocytopeni

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Isoniazidinduceret toksisk hepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epidemiologi, klinik og behandling af SARS-CoV-2 infektion hos børn

    Research output: Contribution to journalReviewpeer-review

  3. Det danske screeningsprogram for hæmoglobinopatier

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Udredning og behandling af mandlig infertilitet

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Malignant pertussis in a three-week-old girl

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Det danske screeningsprogram for hæmoglobinopatier

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Complement split product C3c in saliva as biomarker for periodontitis and response to periodontal treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Extracellular Polysaccharide Matrix of Pseudomonas aeruginosa Biofilms Is a Determinant of Polymorphonuclear Leukocyte Responses

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Protein array-based companion diagnostics in precision medicine

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.
Translated title of the contribution[New treatment options for primary immune thrombocytopenia]
Original languageDanish
JournalUgeskrift for Laeger
Volume173
Issue number4
Pages (from-to)271-4
Number of pages4
Publication statusPublished - 24 Jan 2011

ID: 31047030